Clinical Management of Neuroendocrine Tumors

Clinical trial data inform treatment selection, but dosing, tolerability, and ongoing monitoring shape how that treatment is delivered. This session brings those considerations together for cabozantinib (CABOMETYX®) in patients with previously treated advanced neuroendocrine tumors (NETs).

Bhavesh Shah, RPh, BCOP, Chief Pharmacy Officer, Hematology-Oncology and Specialty Pharmacy at Boston Medical Center Health System, will discuss:

• Treatment considerations for pancreatic and extrapancreatic NETs
• Efficacy and safety findings from the phase 3 CABINET trial
• Dosing and administration, including dose modifications
• Adverse reaction monitoring and management, patient education, and supportive care

Reach out to Johnny Rivera at [email protected] with any questions or login assistance.